Callan Family Office LLC Lowers Stock Position in United Therapeutics Corporation $UTHR

Callan Family Office LLC cut its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 49.0% in the third quarter, Holdings Channel.com reports. The fund owned 1,769 shares of the biotechnology company’s stock after selling 1,699 shares during the period. Callan Family Office LLC’s holdings in United Therapeutics were worth $742,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Norges Bank acquired a new stake in United Therapeutics in the 2nd quarter valued at approximately $136,453,000. Invesco Ltd. boosted its position in shares of United Therapeutics by 90.2% during the second quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock worth $254,219,000 after buying an additional 419,588 shares during the period. AQR Capital Management LLC grew its stake in shares of United Therapeutics by 40.1% in the second quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock valued at $362,876,000 after buying an additional 364,713 shares in the last quarter. Assetmark Inc. grew its stake in shares of United Therapeutics by 38.1% in the second quarter. Assetmark Inc. now owns 715,834 shares of the biotechnology company’s stock valued at $205,695,000 after buying an additional 197,384 shares in the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of United Therapeutics in the 2nd quarter valued at $55,746,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages recently commented on UTHR. UBS Group raised their target price on United Therapeutics from $600.00 to $645.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. Wells Fargo & Company raised their price objective on shares of United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a research note on Thursday, October 30th. Royal Bank Of Canada lifted their price objective on shares of United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a report on Thursday, October 30th. HC Wainwright increased their target price on shares of United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Finally, Morgan Stanley set a $447.00 price target on shares of United Therapeutics in a research note on Wednesday, October 29th. Eight investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $509.50.

Insider Transactions at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 8,300 shares of United Therapeutics stock in a transaction dated Thursday, February 5th. The stock was sold at an average price of $483.25, for a total transaction of $4,010,975.00. Following the completion of the sale, the executive vice president directly owned 36,781 shares of the company’s stock, valued at $17,774,418.25. The trade was a 18.41% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Christopher Causey sold 1,000 shares of the company’s stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $510.00, for a total value of $510,000.00. Following the transaction, the director directly owned 4,190 shares of the company’s stock, valued at approximately $2,136,900. This represents a 19.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 542,214 shares of company stock valued at $260,031,533. Insiders own 10.30% of the company’s stock.

United Therapeutics Stock Down 0.8%

Shares of United Therapeutics stock opened at $478.93 on Friday. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $519.99. The company has a market capitalization of $20.62 billion, a P/E ratio of 18.15, a P/E/G ratio of 2.57 and a beta of 0.85. The company has a 50 day moving average of $486.76 and a 200 day moving average of $425.24.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.